ImmuPharma (IMM) investor relations material

Strategic focus and funding rationale

• P140 remains the primary value driver, with licensing deals expected in 2026 and continued focus on expanding indications.

• Recent funding was driven by long-term shareholders recognizing undervaluation and offering capital to build the company, not financial necessity.

• Decision to advance Kapiglucagon followed strict project evaluation criteria and aims to broaden the portfolio for sustainable growth.

• Dilution concerns are addressed by emphasizing value creation from new projects outweighing percentage ownership loss.

P140 program progress and outlook

• P140 has expanded from a single lupus indication to potential treatment for up to 50 autoimmune diseases, with a new patent filed in September 2025 expiring in 2045.

• Advances include understanding mechanism of action, dosing, and patient identification, enhancing both diagnosis and treatment capabilities.

• Strong interest from multiple potential licensing partners, with a deal anticipated in 2026 and no scientific pushback in discussions.

• Ongoing dialogue with Avion and other partners aims for worldwide progress of P140.

Kapiglucagon opportunity and development plan

• Kapiglucagon targets the Type I diabetes market, addressing the need for a stable, native glucagon formulation for bi-hormonal pumps.

• The product is a prodrug, enabling solubility in saline and efficient conversion to native glucagon, with a planned FDA 505(b)(2) pathway for accelerated approval.

• Market forecasts estimate $3 billion in annual sales post-approval in US/Europe, with conservative market share assumptions.

• Accelerated development timeline of 18–24 months is expected, with potential for early partnership deals and mapped milestones through 2028.

• Patent filed in 2018, expiring in 2038, with potential for further extension.